Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 5/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199295 | 0.85 | NPC1 (0.41) | FGFR3FGFR2FGFR4FGFR1SMN1; SMN2 | |
| SCHEMBL17132546 | 0.81 | CYP1A2 (0.44) | FGFR3FGFR2FGFR4FGFR1SMN1; SMN2 | |
| SCHEMBL17132658 | 0.80 | IRAK4 (0.34) | FGFR3FGFR2FGFR4FGFR1SMN1; SMN2 | |
| SCHEMBL13677497 | 0.78 | NPC1 (0.41) | SMN1; SMN2NPC1RAB9ASCN4AHRH4 | |
| SCHEMBL19545869 | 0.77 | FGFR1 (0.31) | FGFR3FGFR2FGFR4FGFR1KDR | |
| SCHEMBL17132591 | 0.75 | MAP4K4 (0.38) | SMN1; SMN2NPC1RAB9ATP53ALDH1A1 | |
| SCHEMBL13677496 | 0.75 | NOS3 (0.34) | SMN1; SMN2NPC1RAB9ASCN4APDE2A | |
| SCHEMBL10199294 | 0.75 | NPC1 (0.41) | SMN1; SMN2NPC1RAB9ASCN4ATP53 | |
| SCHEMBL10199417 | 0.75 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASCN4APDE10A | |
| SCHEMBL2609301 | 0.74 | NQO2 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| WO-2021160132-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | FGFR3 167/4885FGFR2 546/4885FGFR4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.